News

2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007
Resverlogix Commences Dosing in Phase 3 Clinical Trial BETonMACE
Resverlogix Presents Important New Data at the Annual American Society of Nephrology Kidney Week Conference
Resverlogix Commences Phase 3 Clinical Trial BETonMACE With Apabetalone
Resverlogix Corp. Selected to Present at Cavendish Global Health Impact Forum
Resverlogix Announces Voting Results
Resverlogix Provides Research and Development Update in New York City
Resverlogix Announces the commencement of an Orphan Disease Program specific for Complement Mediated Diseases
Resverlogix Presents at the Rodman & Renshaw 17th Annual Global Investment Conference
Resverlogix Presents New Data at the European Society of Cardiology Congress 2015 on RVX-208 'apabetalone' a Selective BET Inhibitor
International Clinical Steering Committee Announced for Resverlogix's Phase 3 BETonMACE Clinical Trial with RVX-208 "apabetalone"
Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital
Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink
Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement
Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority
Resverlogix to Present at the 2015 Bio International Convention
Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA
Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)
Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement
Resverlogix Receives Two Patents for RVX-208 in China
Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)
Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program
Resverlogix Presents at BIO CEO & Investor Conference
Resverlogix Presents at Biotech Showcase During JP Morgan Week